Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-14

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in adults and children with full-thickness Skin defects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children

NCT03229564

Burns

ACTIVE_NOT_RECRUITING PHASE2

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

NCT03227146

Burns

ACTIVE_NOT_RECRUITING PHASE2

Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects

NCT02145130

Burn Injury Soft Tissue Injury Skin Necrosis +3 more

COMPLETED PHASE1

A Study to Evaluate the Efficacy of an Acellular Dermal Template for the Treatment of Full Thickness Skin Defects

NCT02373566

Full Thickness Skin Defects

COMPLETED NA

Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

NCT06745557

Burns

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicentre phase II clinical trial will target adults and children with fullt-thickness skin defects to elucidate the benefit of a tissue-engineered autologous skin substitute. Particular emphasis, apart from safety, will be placed on efficacy, e.g. scar quality, in comparison to meshed STSG.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Wound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Option 1

Location A is the experimental area and Location B is the control area.

Group Type OTHER

EHSG-KF

Intervention Type BIOLOGICAL

Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

STSG

Intervention Type BIOLOGICAL

Transplantation of autologous split-thickness skin graft to the control area

Option 2

Location A is the control area and Location B is the experimental area.

Group Type OTHER

EHSG-KF

Intervention Type BIOLOGICAL

Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

STSG

Intervention Type BIOLOGICAL

Transplantation of autologous split-thickness skin graft to the control area

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EHSG-KF

Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention Type BIOLOGICAL

STSG

Transplantation of autologous split-thickness skin graft to the control area

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

denovoSkin Split-thickness skin graft

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: ≥1 years of age
* Large full-thickness defects that require coverage after excision of: Scars, Benign skin tumors (e.g. neurofibroma), Melanocytic nevus (e.g. giant nevus), Gender reassignment surgery, Soft tissue defect after trauma, Soft tissue defect after infection and debridement (e.g necrotizingn fascitis, hidadentitis suppurativa, purpura fulminans), Flap donorsite (e.g. radial forearm flap)
* Minimal areas requiring coverage (not counting the head and neck area for study patients in The Netherlands): 1-5 years: minimum 9cm2, 6-16 years: minimum 25cm2, \>16 years: minimum 45cm2
* Signed Informed consent

Exclusion Criteria

* Patients tested positive for HBV, HCV, syphilis or HIV
* Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. systemic skin and connective tissue diseases, any kind of congenital defect of metabolism including insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired immunosuppressive condition, chronic renal failure, or chronic hepatic dysfunction (Child-Pugh class B or C), severe malnutrition, or other concomitant illness which, in the opinion of the Investigator, has the potential to significantly delay wound healing)
* Severe drug and alcohol abuse
* Pre-existing coagulation disorders as defined by INR outside its normal value, PTT \>ULN and fibrinogen \<LLN prior to the current hospital admission and / or at the Investigator's discretion
* Patients with known allergies to amphotericin B, gentamicin, penicillin, streptomycin, or bovine collagen
* Previous enrolment of the patient into the current phase II study
* Participation of the patient in another study with conflicting endpoints within 30 days preceding and during the present study
* Patients expected not to comply with the study protocol (including patients with severe cognitive dysfunction/impairment and severe psychiatric disorders)
* Pregnant or breast feeding females
* Intention to become pregnant during the clinical course of the study (12 months)
* Enrolment of the Investigator, his/her family members, employees and other dependent persons

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No